Table 2.

Patient characteristics at antiretroviral treatment initiation among adolescent and youth patients (10–24 years) at 109 health facilities in Kenya during 2006–2011 (N=8016)^a.

			Age at enrollment
	Total		10–14 years		15–19 years		20–24 years
	N	%	n	%	n	%	n	%
	8016	100	1716	21.4	1240	15.5	5060	63.1
Age at ART initiation (years)
10–14	1623	20.3	1623	94.6	0	0	0	0
15–19	1235	15.4	93	5.4	1142	92.1	0	0
20–24	4655	58.1	0	0	98	7.9	4557	90.1
>25 years at ART	503	6.3	0	0	0	0	503	9.9
Sex
Male	1818	22.7	840	49.0	350	28.3	628	12.4
Female	6196	77.3	876	51.0	889	71.7	4431	87.6
WHO stage
Stage I	929	15.8	110	9.5	153	16.9	666	17.5
Stage II	1858	31.6	445	38.4	267	29.5	1146	30.1
Stage III	2833	48.3	546	47.2	447	49.5	1840	48.3
Stage IV	250	4.3	57	4.9	37	4.1	156	4.1
Missing	2146	26.8	558	32.5	336	27.1	1252	24.7
ART initiation year
2006	668	8.3	204	11.9	131	10.6	333	6.6
2007	1222	15.2	298	17.4	178	14.4	746	14.7
2008	1385	17.3	325	18.9	228	18.4	832	16.4
2009	1634	20.4	346	20.2	224	18.0	1064	21.0
2010	1715	21.4	324	18.9	249	20.1	1142	22.6
2011	1145	14.3	194	11.3	182	14.7	769	15.2
2012	244	3.0	24	1.4	47	3.8	173	3.4
CD4+ cell count median (IQR)	189 (87–284)		199 (80–341)		185 (73–277)		188 (91–275)
350+	725	12.9	259	23.4	107	12.4	359	9.9
200–350	1898	33.8	289	26.1	286	33.1	1323	36.4
100–199	1420	25.3	236	21.3	217	25.1	967	26.6
<100	1568	28.0	322	29.1	255	29.5	991	27.2
Missing	2405	30.0	610	35.6	375	30.2	1420	28.1
Facility type
Public primary	1538	19.4	264	15.5	237	19.3	1037	20.8
Public secondary/tertiary	5530	69.8	1198	70.5	848	69.2	3484	69.8
Private and others	851	10.8	238	14.0	141	11.5	472	9.5
Site location
Urban/semi-urban	4705	59.4	1028	60.5	730	59.5	2947	59.0
Rural	3214	40.6	672	39.5	496	40.5	2046	41.0
		Year of ART initiation
	Total		2006–2007		2008–2009		2010–2011
	8014		2585	32.3	3248	40.5	2183	27.2
Sex
Male	1818	22.7	625	24.2	739	22.8	454	20.8
Female	6196	77.3	1958	75.8	2509	77.2	1729	79.2
Age at ART initiation (years)
10–14	1623	20.3	623	24.1	672	20.7	328	15.0
15–19	1235	15.4	419	16.2	470	14.5	346	15.9
20–24	4655	58.1	1313	50.8	1910	58.8	1432	65.6
>25 years at ART	503	6.3	230	8.9	196	6.0	77	3.5
WHO stage
Stage I	929	15.8	156	8.7	361	15.0	412	24.8
Stage II	1858	31.6	450	25.1	773	32.1	635	38.2
Stage III	2833	48.3	1096	61.1	1183	49.1	554	33.3
Stage IV	250	4.3	92	5.1	95	3.9	63	3.8
Missing	2146	26.8	791	30.6	836	25.7	519	23.8
CD4+ cell count median (IQR)	189 (87–284)		170 (71–261)		189 (88–280)		215 (105–303)
350+	725	12.9	203	13.0	307	13.0	216	12.7
200–350	1898	33.8	428	27.5	791	33.6	679	40.0
100–199	1420	25.3	423	27.5	607	25.8	390	23.0
<100	1568	28.0	505	32.4	649	27.6	414	24.4
Missing	2405	30.0	1027	39.7	894	27.5	484	22.2
Facility type
Public primary	1538	19.4	230	8.9	642	20.0	666	31.4
Public secondary/tertiary	5530	69.8	2101	81.5	2211	68.7	1218	57.3
Private and others	851	10.8	246	9.6	365	11.3	240	11.3
Site location
Urban/semi-urban	4705	59.4	1822	70.7	1846	57.4	1037	48.8
Rural	3214	40.6	755	29.3	1372	42.6	1087	51.2

^aAll the variables were statistically associated with age group or enrolment year cohort (P <0.001), except for site location by age group (P = 0.57).